Print

Cytori Therapeutics, Inc. (CYTX) Announces Independent Clinical Study Results in Breast Reconstruction Presented at the Association of Breast Surgery Conference  
5/17/2011 9:24:54 AM

ZUG, Switzerland--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ:CYTX) reports that surgeons from North Tees and Hartlepool NHS Foundation Trust have presented clinical outcomes using Adipose-Derived Regenerative Cell (ADRC) fat grafting in reconstructive breast surgery at the Association of Breast Surgery Conference in Manchester, UK, May 16-17, 2011. The procedure, referred to by Cytori as RESTORE, was separately investigated in Cytori’s own RESTORE 2 trial.